Patients of GC with T4b stage, gastrectomy and additional combined resection may be the only way for a potential cure. However, radical resection for cT4b gastric cancer may increase potential postoperative complications and carries a high risk of R1/R2 resection, especially when pancreatic head or liver are involved. Moreover, GC at the T4b stage often presents with high lymph nodes metastasis and peritoneal spread, which contribute to poorly survival outcomes [6, 9, 11, 12, 17, 20, 21]. Therefore, multivisceral resection for T4b gastric cancer remains controversial. This disorder should be treated as a separate group to achieve better survival outcomes.
In our study, we expected to improve long-term survival and minimize the toxicity and adverse events of patients with T4b GC by applying neoadjuvant chemotherapy with DCS regimen, followed by gastrectomy and lymphadenectomy. The findings demonstrated much better efficacy than initially anticipated, with high compliance rate (88.4%), R0 resection rate (72.0%), low toxicities and adverse events, and satisfactory survival (3-year OS of 49%). These results enhanced the use of neoadjuvant chemotherapy with DCS regimen followed by gastrectomy and lymphadenectomy in this population, which has not been reported before.
Besides the regimen for neoadjuvant chemotherapy, the dosage is also a critical factor in increasing the response rate and reducing toxicity. In Japan, a 2–3 cycle DCS (docetaxel, cisplatin and S-1) or CS (cisplatin and S-1) regimen was utilized for preoperative chemotherapy for GC with advanced stage or extended lymph node metastasis. However, there were a relatively high incidence of grade 3 or grade 4 toxicity and adverse events, particularly leukopenia (18.9–27.5%), neutropenia (19.0–55.0%), diarrhea (7.5–10%) [32–36]. A higher dose of docetaxel and cisplatin was supposed to be related to a higher incidence of grade 3–4 hematological toxicity [41–43]. In our study, the total dose of docetaxel (70 mg/m2/cycle) and cisplatin (70mg/m2/cycle), which was higher than in other studies, was adjusted by dividing it into biweekly schedules to reduce toxicity adverse effects. The dose intensity of docetaxel (17.5 mg/m2/week), cisplatin (17.5 mg/m2/week), and S-1 (280 mg/m2/week) were relatively higher in other trials. However, most of the toxicity and adverse events were in grade 1 or 2, while grade 3 or 4 of neutropenia and anemia were 20.9%, and 13.9%, respectively. These results were remarkably lower than reported in the other studies. Thus, a high completion and tolerance rate was obtained in our study population with this modified schedule.
Regarding postoperative complications of gastrectomy and radical lymphadenectomy after neoadjuvant chemotherapy, the overall complication rate in our study was similar to several prior studies [32, 33, 43–46]. However, no patient experienced severe complications (ClavienDindo > = 3) in this study. Performing a radical resection for cT4b gastric cancer without neoadjuvant chemotherapy may increase the complexity of the operation and pose potential postoperative complications in certain cases, particularly when the pancreas and liver are involved. Some authors hypothesized that extensive resection was linked to a higher incidence of overall severe complications and mortality [14, 20]. Conversely, recent studies support the notion that there is no disparity in postoperative complications between multivisceral resection and gastrectomy alone [6, 7, 10, 11]. In our study, seven patients underwent combined resection, 21 patients underwent D2 resection, 2 patients underwent D1 + resection, and 2 patients underwent D2 + PAND. We didn't have any cases of severe complications such as anastomotic leak, bleeding, or severe complications after surgery. The feasibility and safety of extended gastrectomy were previously advocated, and our results are relatively better to those without neoadjuvant chemotherapy reported in the literature [2, 5, 7, 8, 10, 12, 13, 15–17].
The adjuvant chemotherapy approach is required to improve the curability and survival outcome for T4b GC. Although MVR was considered safe and feasible with high rate of R0 resection for T4b gastric cancer, several previous studies demonstrated that initiation of adjuvant chemotherapy might be prolonged or even prohibited due to patient derailing after a large MVR. The rate of adjuvant chemotherapy was low (41–75%), resulting in unsatisfactory survival outcomes with 3-year OS of 10.8–39.0% [4, 6, 7, 9, 11, 12]. In this manner, our study was among the limited data demonstrating the efficacy of neoadjuvant chemotherapy for T4b GC, with high rate of complete adjuvant chemotherapy (83.3%), low toxicities and morbidities, and satisfactory 3-year OS (49%) and DFS (38%). These findings were superior to those of previous studies, in which MVR surgery was performed without neoadjuvant chemotherapy [1–21]. Based on these results, we suggest applying neoadjuvant chemotherapy with DCS regimen over upfront surgery and adjuvant chemotherapy for T4b GC.
Analyzed by univariate regression, our findings indicated that pathological lymph node stage and incomplete adjuvant chemotherapy significantly reduced the overall survival. However, due to the small sample size, the multivariable analyses did not reveal any independent risk factors. Several previous studies have identified the incompleteness of resection, lymph node metastasis, and the number of resected organs as independent prognostic factors for T4b GC. Among these, the most powerful prognostic factor was the completeness of resection, which has been confirmed by almost all the published studies [3, 5, 7–11, 19–21].
This study had some limitations. Firstly, although the findings were potential, it was still a single-arm retrospective study at a single institution. Thus, controlled trials are required to propose a stronger recommendation. Secondly, the 5-year survival outcomes could not be evaluated in this study. We expected to report these outcomes in further study after a sufficient length of follow-up. Thirdly, the number of patients included in this study was relatively small when divided into separate groups, and further evaluations are required in larger populations.
In conclusion, neoadjuvant chemotherapy with DCS regimen followed by gastrectomy and lymphadenectomy demonstrated a high tolerance, high tumor response rate, sufficient R0 resection rate, high complete adjuvant chemotherapy rate and satisfactory 3-year survival outcomes for GC with T4b. Preoperative DCS regimen with 3–4 cycles was a promising approach for GC with T4b stage.